Monday, 28 November 2016

Costly Biotech Bet Still Worth It for J&J

A deal for Actelion Pharmaceuticals would help Johnson & Johnson generate growth.

from WSJ.com: Markets http://ift.tt/2gbzLGC
via https://ifttt.com/ IFTTT
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)